ADC Therapeutics SA
ADC Therapeutics SA logo
ADCT

ADC Therapeutics SA (ADCT)

$3.484.92%

Market is closed
– opens on 8 PM, 02 Dec 2022
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$3.39
Day's Range
$3.73
$3.31
52-Week Range
$23.28
1 month return15.74%
3 month return45.88%
1 year return84.48%
5 year return88.26%

Company Information

ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors. The Company has created a deep clinical pipeline by combining its decades of experience and strategic target selection with proprietary next-generation pyrrolobenzodiazepine (PBD) technology. The Company's Biologics License Application for its lead product candidate, loncastuximab tesirine (Lonca, formerly ADCT-402) for the treatment of relapsed or refractory diffuse large B-cell lymphoma was given priority review status by the U.S. Food and Drug Administration and a Prescription Drug User Fee Act (PDUFA) target date of May 21, 2021. The Company's second lead product candidate, camidanlumab tesirine (Cami, formerly ADCT-301), is being evaluated in a 117-patient pivotal Phase 2 clinical trial for the treatment of relapsed or refractory Hodgkin lymphoma.
OrganizationADC Therapeutics SA
Employees312
CEODr. Ameet Mallik M.B.A., M.S.
IndustryHealth Technology

Analyst Recommendation

based on 7 analysts ratings

Buy
100%
Buy
0%
Hold
0%
Sell

Based on 7 Wall street analysts offering stock ratings for ADC Therapeutics SA(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 307.18%

Current

$3.48

Target

$14.17

Recommendation Trend

Based on 7 analyst

Current1M Ago3M Ago
Buy
7
10
12
Hold
0
2
1
Sell
0
1
0
Consensus
BUY
BUY
BUY

Highlights

Market Capitalization
262.4M
Book Value
$1.34
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-2.54
Wall Street Target Price
14.17

Valuation

Trailing PE0.0
Forward PE0.0
Price/Book (mrq)
2.52
Enterprise Value
-209048
Enterprise Value/Revenue
0.13
Enterprise Value/Ebitda
0.0

Technicals

Beta
1.18
50 Day MA
4.5
200 Day MA
8.63

Institutional Holdings

FMR Inc

9.89%

Redmile Group, LLC

9.67%

JPMorgan Chase & Co

4.45%

AllianceBernstein L.P.

3.81%

Deerfield Management Co

3.08%

T. Rowe Price Associates, Inc.

2.53%

Discover more

Frequently Asked Questions

What is ADC Therapeutics SA share price today?

Can Indians buy ADC Therapeutics SA shares?

How can I buy ADC Therapeutics SA shares from India?

Can Fractional shares of ADC Therapeutics SA be purchased?

What are the documents required to start investing in ADC Therapeutics SA stocks?

What are today’s High and Low prices of ADC Therapeutics SA?

What are today’s traded volumes of ADC Therapeutics SA?

What is today’s market capitalisation of ADC Therapeutics SA?

What is the 52 Week High and Low Range of ADC Therapeutics SA?

How much percentage ADC Therapeutics SA is down from its 52 Week High?

How much percentage ADC Therapeutics SA is up from its 52 Week low?

What are the historical returns of ADC Therapeutics SA?

Who is the Chief Executive Officer (CEO) of ADC Therapeutics SA?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*